# Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

> **NCT00439777** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 4833 (actual)

## Conditions studied

- Pulmonary Embolism

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Enoxaparin overlapping with and followed by VKA

## Key facts

- **NCT ID:** NCT00439777
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2011-09
- **Final completion:** 2011-12
- **Target enrollment:** 4833 (ACTUAL)
- **Last updated:** 2014-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00439777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00439777, "Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00439777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*